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TrafﬁckingThe intracellular trafﬁcking of different VP22-enhanced yellow ﬂuorescent protein (EYFP) fusion proteins
expressed by bovine herpesvirus-1 (BHV-1) recombinants was examined by live-cell imaging. Our results
demonstrate that (i) the fusion of EYFP to the C terminus of VP22 does not alter the trafﬁcking of the protein
in infected cells, (ii) VP22 expressed during BHV-1 infection translocates to the nucleus through three
different pathways, namely early mitosis-dependent nuclear translocation, late massive nuclear transloca-
tion that follows a prolonged cytoplasmic stage of the protein in non-mitotic cells, and accumulation of a
small subset of VP22 in discrete dot-like nuclear domains during its early cytoplasmic stage, (iii) the addition
of the SV40 large-T-antigen nuclear localization signal (NLS) to VP22-EYFP abrogates its early cytoplasmic
stage, and (iv) the VP22 131PRPR134 NLS is not required for the late massive nuclear translocation of the
protein, but this motif is essential for the targeting of VP22 to discrete dot-like nuclear domains during the
early cytoplasmic stage. These results show that the amount of VP22 in the nucleus is precisely regulated at
different stages of BHV-1 infection and suggest that the early pathways of VP22 nuclear accumulation may be
more relevant to the infection process as the late massive nuclear inﬂux starts when most of the viral
progeny has already emerged from the cell.
© 2009 Elsevier Inc. All rights reserved.Introduction
A unique feature of the herpesvirus virion is the presence of a
complex proteinaceous compartment, the tegument, located between
the nucleocapsid and the virus envelope. Various functions, including
modulation of transcription, kinase activity, RNase activity, and DNA
packaging have been ascribed to some tegument proteins suggesting
that these virion constituents function at several stages during virus
infection, establishing conditions for efﬁcient viral replication and
promoting virus assembly and egress (Fuchs et al., 2002; Koppers-
Lalic et al., 2001; Misra et al., 1995; Purves and Roizman, 1992; Read
et al., 1993; Salmon et al., 1998; Wysocka and Herr, 2003).
The BHV-1 UL49 gene product, VP22, is a 258 amino acid (aa)
tegument phosphoprotein which is dispensable for virus growth in
tissue culture (Liang et al., 1995). Although in addition to its role as a
virion component VP22 may have regulatory functions, its precise
biological role in BHV-1 infection is not known. A comparative study of
transiently expressed BHV-1 and herpes simplex virus type 1 (HSV-1)
VP22-green ﬂuorescent protein (GFP) fusions showed that both
proteins exhibit unusual characteristics including microtubule asso-
ciation, nuclear localization, non-classical intercellular trafﬁcking and
ability to bind chromatin of mitotic cells (Harms et al., 2000). The
observation that UL49-knockout BHV-1 has reduced virulence in cattleDrunen Littel-van den Hurk).
ll rights reserved.suggests a functional role for VP22 in virus replication in vivo (Liang
et al., 1997). The decrease in histone H4 acetylation detected in BHV-1
VP22-expressing cells further supports the contention that VP22 may
exert regulatory functions (Ren et al., 2001a).
Although in silico prediction did not reveal any canonical NLS in
the structure of BHV-1 VP22 (Zheng et al., 2005), which would be
recognized by members of the importin family of cellular transporters
(reviewed in Alvisi et al., 2008), transient transfection experiments
with plasmids expressing GFP-tagged variants of BHV-1 VP22 have
shown that the nuclear localization of the protein is not dependent on
other viral factors (Harms et al., 2000; Ren et al., 2001a; Zheng et al.,
2005). There is strong evidence that the C-terminus of BHV-1 VP22 is
required for nuclear targeting (Ren et al., 2001a; Zheng et al., 2005;
Zhu et al., 2005). Furthermore, one study suggested that the nuclear
targeting motif of BHV-1 VP22 is a 103-aa long non-canonical
conformation-sensitive nuclear localization signal (NLS) spanning
residues 130 to 232 (Zhu et al., 2005), whereas other data provided
evidence for a BHV-1 VP22 nuclear targeting domain between aa 121
and 139, and a functional non-classical NLS between residues 131 and
134 (Zheng et al., 2005). The ﬁrst study also demonstrated that a 103-
aa sequence which is required for nuclear targeting of VP22 binds
histones permitting nuclear retention (Zhu et al., 2005). However, the
subcellular localization of VP22 in BHV-1-infected cells was deﬁned as
nuclear based on studies that covered only late stages of infection
(Liang et al., 1995; Ren et al., 2001a, 2001b).
It was shown by indirect immunoﬂuorescence analysis that PRV
VP22 predominantly localizes to the nucleus throughout the infectious
190 V.A. Lobanov et al. / Virology 396 (2010) 189–202cycle (del Rio et al., 2002), whereas there is some controversy
regarding the trafﬁcking of HSV-1 VP22 in infected cells. HSV-1 VP22
was found to possess a pronounced cytoplasmic stage early in
infection, followed by translocation to the nucleus at a later time
(Pomeranz and Blaho, 1999). However, by time-lapse examination of
live cells infectedwith recombinantHSV-1 expressingVP22with anN-terminal GFP fusion, the protein appeared to be almost entirely
cytoplasmic throughout the infection course (Elliott and O'Hare,
1999). Recently, however, VP22 with monomeric red ﬂuorescent
protein fused to its N-terminus completely translocated to the nucleus
by 16 h after a high multiplicity infection with a triply ﬂuorescent-
tagged HSV-1 (Sugimoto et al., 2008).
191V.A. Lobanov et al. / Virology 396 (2010) 189–202In this study we performed a detailed examination of VP22
trafﬁcking in BHV-1-infected cells by constructing and exploiting
BHV-1 recombinants expressing different VP22-EYFP fusions. This
demonstrated that BHV-1 VP22 employs three different translocation
pathways to gain access to the nucleus, namely early mitosis-
dependent nuclear translocation in a subset of postmitotic cells, late
massive nuclear translocation that followed a prolonged cytoplasmic
stage of the protein in non-dividing cells, and accumulation of a small
subset of VP22 in faint dot-like nuclear domains during its early
cytoplasmic stage. Mutation of the earlier described VP22 131PRPR134
NLS did not alter the late massive nuclear translocation kinetics of the
protein, but abrogated its accumulation in discrete dot-like nuclear
domains during the early cytoplasmic stage, suggesting that this motif
is functionally signiﬁcant during infection. Finally, we showed that
BHV-1 VP22 is represented by three differently phosphorylated
isoforms closely migrating in denaturing gels and that all isoforms
including the highest-mobility nonphosphorylated isoform can be
detected in the nuclear fraction collected after the onset of the late
massive nuclear translocation of the protein, which suggests that
phosphorylation of VP22 is not required for this nuclear translocation
pathway.
Results
Construction and characterization of recombinant BHV-1-UL49-EYFP
Although previous studies suggested that the subcellular localiza-
tion of BHV-1 VP22 in infected cells was predominantly nuclear, all
data demonstrating the nuclear accumulation of VP22 were obtained
by indirect immunoﬂuorescence analysis of BHV-1-infected cells ﬁxed
at late stages of infection (Liang et al., 1995; Ren et al., 2001a, 2001b).
To undertake a detailed study of the subcellular localization of VP22
during BHV-1 infection, we constructed a recombinant BHV-1 (BHV-
1-UL49-EYFP) in which the UL49 gene was replaced with a modiﬁed
gene encoding VP22 fused to EYFP (Fig. 1A). Correct VP22 modiﬁca-
tion was veriﬁed by Southern hybridization. According to the
published sequence of the entire BHV-1 genome (GenBank accession
number: NC_001847), the UL49 gene is located within a 5,479 bp SphI
fragment. However, our results demonstrated binding of the UL49-
speciﬁc probe to the UL49 gene sequence located within a 13,052 bp
SphI fragment, indicating that the SphI restriction site spanning
nucleotides 13,052–13,057 of the Cooper strain genome is missing
from the BHV-1 strain 108 genome (Fig. 1B). As expected, the in-
frame fusion of the EYFP sequence to the UL49 ORF resulted in the
addition of 760 nucleotides to the UL49 gene-containing restriction
fragment, resulting in hybridization of the UL49-speciﬁc probe to the
13,812 bp SphI fragment of the BHV-1-UL49-EYFP genome. The EYFP-
speciﬁc probe hybridized only to the 13,812 bp fragment of the BHV-
1-UL49-EYFP genome, but not to the 13,052 bp fragment of wt BHV-1
DNA (Fig. 1B), conﬁrming the presence of the desired VP22
modiﬁcation. Correct recombination was further conﬁrmed by PCR
ampliﬁcation and sequencing of the ampliﬁed fragment of the
recombinant BHV-1 genome containing the UL49-EYFP gene (data
not shown).Fig. 1. Characterization of BHV-1-UL49-EYFP. (A) Schematic representation of the BHV-1-U
blotting. Viral DNA isolated from either wt BHV-1 (WT) or BHV-1-UL49-EYFP (UL49-EY
electrophoresis and transfer to a nylon membrane. The membrane was hybridized with a U
EYFP gene-speciﬁc probe. The standard DNA marker values in base pairs are depicted on the
kinetics for VP22, VP16, and VP8. MDBK cells infected with either wt BHV-1 (WT) or BHV-1
then every 4 h for 24 h after infection. Equal amounts of whole-cell extracts were analyz
antibody, anti-GFP antibody, VP16-speciﬁc antibody or antibody against VP8. M, whole-cell
masses in kilodaltons. (D) Viral growth curves. Cell culture medium and cells were harvested
infected with 0.01 PFU/cell of either wt BHV-1 (WT) or BHV-1-UL49-EYFP (UL49-EYFP). Th
assay onMDBK cells. EC, extracellular virus released to the cell culture medium. IC, intracellul
of gradient-puriﬁed virions of wt BHV-1 (WT) or BHV-1-UL49-EYFP (UL49-EYFP) were an
immunoblotting with polyclonal antibodies against VP22, GFP, VP5, or VP16 (right panel).To ensure that recombinant BHV-1-UL49-EYFP expresses VP22-
EYFP and has similar growth characteristics to the parental virus, we
compared the expression kinetics of VP22-EYFP and two other
tegument proteins for both viruses. Immunoblotting with both
VP22-speciﬁc and GFP-speciﬁc antibodies conﬁrmed that BHV-1-
UL49-EYFP expresses the fusion protein with the correct apparent
molecularmass, around 63 kDa, corresponding to combinedmolecular
masses of VP22 and EYFP (Fig. 1C). The overall expression kinetics of
VP22-EYFP was similar to that of wild-type VP22, and two other
tegument proteins, VP8 and VP16, also displayed identical kinetics of
synthesis in both viruses. The separation conditions of this experiment
allowedus to detect at least two isoformsof unmodiﬁedVP22 (Fig. 1C).
The increase in molecular mass of the protein after EYFP tag incor-
poration led these isoforms to be less discernible. However, analysis of
the same whole-cell lysates of BHV-1-UL49-EYFP-infected cells by
longer electrophoresis in a lower density polyacrylamide gel (SDS-6%
PAGE), followed by immunoblotting with GFP-speciﬁc antibody
conﬁrmed the presence of two closely migrating VP22-EYFP isoforms
(data not shown). To compare the growth characteristics of wt BHV-1
and BHV-1-UL49-EYFP in cultured cells, we carried out viral growth
curves. The titers of extracellular and cell-associated virus were
measured by plaque assay on MDBK cells. As expected, both viruses
replicated to the same titers in cell culture. The replication kinetics of
both viruses was similar, except for a minor delay in the release of
extracellular virions demonstrated by the recombinant virus (Fig. 1D).
In order to verify whether VP22-EYFP was incorporated into viral
particles, we puriﬁed extracellular virions of BHV-1-UL49-EYFP or wt
BHV-1 on 10% to 60% linear potassium sodium tartrate gradients and
analyzed solubilized virion proteins by SDS-PAGE, followed by either
staining with Coomassie blue or Western blotting. While a 35 kDa
species corresponding to unmodiﬁed VP22 was readily detectable in
the total protein proﬁle of wt BHV-1 virions, this species was absent in
the proﬁle of BHV-1-UL49-EYFP particles (Fig. 1E, left panel).
Although the results of Coomassie staining showed that VP22-EYFP
has a similar molecular mass to VP16 and co-migrates with VP16 in
the gel, Western blotting with both VP22-speciﬁc and GFP-speciﬁc
antibodies clearly demonstrated efﬁcient packaging of the VP22-EYFP
fusion protein into the virus particle (Fig. 1E, right panel). These
results suggested that VP22-EYFP is efﬁciently packaged into virions.
Subcellular localization of VP22-EYFP in viral plaques
During plaque puriﬁcation of BHV-1-UL49-EYFP we noticed
different compartmentalization of VP22-EYFP in central cells of a
plaque compared with cells located closer to the periphery. To further
demonstrate this phenomenon, MDBK cells cultured on a coverslip
were infected with 0.001 PFU/cell of recombinant virus, and live
imaging of discrete viral plaques was performed at 36 h p.i. VP22-
EYFP demonstrated three different subcellular distributions in the
cells of well-developed BHV-1-UL49-EYFP-induced plaques, namely
cytoplasmic, equal distribution throughout the cell, and predomi-
nantly nuclear (Fig. 2, panel A). The nuclear localization of the protein
was inherent to the cells located in the center of a plaque, which are at
a late stage of infection, whereas in peripheral cells the proteinL49-EYFP genome. The ruler on the top shows the DNA size in base pairs. (B) Southern
FP) gradient-puriﬁed virions was digested with SphI, followed by 0.8% agarose gel
L49 gene-speciﬁc probe. Then the membrane was stripped and re-hybridized with an
left and right sides of the panels. (C) The recombinant virus has wild-type expression
-UL49-EYFP (UL49-EYFP) at a multiplicity of 10 PFU/cell were collected at 1 h, 4 h and
ed by SDS-PAGE in 16×16 cm gels, followed by Western blotting with VP22-speciﬁc
extracts of mock-infected cells. The values on the left side of the panels are molecular
separately every 4 h up to 32 h and at 48 h p.i. from tissue culture ﬂasks withMDBK cells
e titer of infectious virus progeny in each sample was determined by standard plaque
ar virus. (E) Packaging of the VP22-EYFP fusion protein into virions. Solubilized proteins
alyzed by SDS-10% PAGE, followed by either Coomassie blue staining (left panel) or
VP22, VP22-EYFP, VP16, VP8, and VP5 species are indicated.
Fig. 2. Analysis of VP22 localization within the cells of discrete BHV-1-UL49-EYFP-induced or wt BHV-1-induced plaques. To analyze the recombinant virus-derived plaques, a 40mm
glass coverslip with MDBK cells infected at a MOI of 0.001 was assembled into the FCS2 temperature control chamber and images of ﬂuorescent plaques were collected at 36 h p.i.
Panel A represents a BHV-1-UL49-EYFP-induced well-developed plaque. The localization of VP22 within the cells of wt BHV-1-induced plaques was analyzed by indirect
immunoﬂuorescence with VP22-speciﬁc antibody and FITC-conjugated goat anti-rabbit IgG secondary antibody. A representative image of wt BHV-1-induced plaque (36 h p.i.) is
depicted in panel B.
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localization patterns of VP22 were detected in cells of wt BHV-1-
induced plaques by indirect immunoﬂuorescence with VP22-speciﬁc
antibody (Fig. 2, panel B), indicating that the addition of the EYFP tag
did not alter the trafﬁcking of VP22 in infected cells. These results
suggest that BHV-1 VP22 displays pronounced cytoplasmic localiza-
tion early during infection and translocates to the nuclei of infected
cells at a later stage of infection.
The kinetics of the massive nuclear translocation of VP22 in infected cells
To investigate the kinetics of VP22-EYFP translocation to the nuclei
of infected cells in more detail, we carried out time lapse microscopy
analysis of live BHV-1-UL49-EYFP-infected MDBK cells. The cells were
infected at a MOI of 10 to achieve uniform infection of the entire
monolayer and examined for EYFP ﬂuorescence every hour from 2 to
20 h p.i. Since preliminary experiments indicated that recurring
acquisition of multiple z-sections from a single ﬁeld of the MDBK cell
monolayer had a phototoxic effect on the cells which led to earlier
translocation of VP22-EYFP to the nuclei of impaired cells, we
captured z-stacks from different spots across the monolayer.
Representative images produced by stacking z-series collected at
each time point are demonstrated in Fig. 3A. A weak diffuse
cytoplasmic VP22-EYFP ﬂuorescence was ﬁrst detected at 3 h after
infection and increased in intensity over the next few hours. Intense
ﬂuorescent dots grouped in clusters located on one side of the cell
nucleus in a pattern resembling the Golgi system location became
clearly detectable in cells of the entire monolayer by 4 h p.i. and
increased in intensity over the next 2 h. By 7 h p.i., intensely
ﬂuorescent particulate material started to accumulate in the cyto-
plasm including the plasma membrane region. Over the next 2 h the
ﬂuorescence of this material increased in intensity, and by 10 h p.i.
VP22-EYFP ﬂuorescence became readily detectable in the nuclei of
infected cells with protein accumulation in the perinuclear space,
changing the overall pattern of VP22-EYFP localization from cyto-
plasmic to equal distribution throughout the cell. As the infection
progressed over the next few hours, the intensity of VP22-EYFP
ﬂuorescence in the nuclei of infected cells gradually increased
whereas the cytoplasmic ﬂuorescence intensity declined. By 14 h p.
i., the nuclear fraction of VP22-EYFP was prevalent, and the protein
displayed predominantly nuclear localization over the remainder of
the time course. Thus, these results are indicative of a prolonged
cytoplasmic phase of VP22-EYFP (up to 9 h at a MOI of 10) before its
gradual translocation into the nuclei of infected cells.Since the addition of the EYFP tag could alter the kinetics of the
nuclear accumulation of VP22, we also determined whether the
nuclear localization observed for VP22-EYFP applies to unmodiﬁed
VP22. MDBK cells cultured on Lab-Tek chamber slides were infected
with 10 PFU/cell of wt BHV-1, ﬁxed every 2 h up to 12 h p.i. and
immunostained using VP22-speciﬁc antibodies (Fig. 3B). Like the
VP22-EYFP fusion, unmodiﬁed VP22 was restricted mainly to the
cytoplasm up to 8 h p.i., and became clearly detectable in the nuclei of
infected cells by 10 h p.i. Thus, the overall kinetics of the nuclear
accumulation of unmodiﬁed VP22 and VP22-EYFP was similar further
conﬁrming the absence of any alterations in VP22 trafﬁcking due to
the introduced modiﬁcation.
The mitosis-dependent pathway of BHV-1 VP22 nuclear accumulation
The massive nuclear accumulation at late stages of infection was
not the only VP22 nuclear translocation pathway observed during our
experiments. Even at early stages of infection there was a subpopu-
lation of postmitotic cells with nuclear localization of the protein. The
high capability of BHV-1 and HSV-1 VP22 homologues to bind
chromatin in cells progressing through mitosis was demonstrated by
transient transfection with plasmids expressing GFP-tagged variants
of these proteins (Elliott and O'Hare, 2000; Harms et al., 2000; Ren
et al. 2001a).
To demonstratemitosis-dependent translocation of BHV-1 VP22 to
the nucleus in infected cells, we examined live MDBK cells infected
with 5 PFU/cell of BHV-1-UL49-EYFP. At 4 h p.i. cytoplasmic VP22-
EYFP ﬂuorescence became readily detectable in cells of the entire
monolayer, but in mitotic cells the protein was tightly associated with
chromatin without any detectable ﬂuorescence in the cytoplasm
(Fig. 4A, panel a). Consequently, VP22-EYFP remained in the nuclei of
postmitotic cells after the reformation of the nuclear membrane
(Fig. 4A, panel b). The kinetics of this process is illustrated in Fig. 4B. A
mitotic cell with VP22-EYFP-labeled chromatin of metaphase chro-
mosomes was selected at 4 h p.i. (Fig. 4B, 0′), and z-series were
collected every 10 min. The sequence of images shown in Fig. 4B
demonstrates how the infected cell normally progressed through
mitosis as metaphase was followed by anaphase (Fig. 4B, 10′) and
then telophase (Fig 4B, 20′), resulting in VP22-EYFP being ﬁnally
retained in the nuclei of daughter cells (Fig. 4B, 30′). At later time
points, around 7 h p.i., we did not detect any complete mitosis events
but, instead, a subpopulation of cells with VP22-EYFP outlining the
condensed chromosomes located in a prometaphase-like pattern was
prominent (data not shown). Thus, even at high multiplicity of
Fig. 3. Time lapse live-cell imaging of VP22 subcellular localization during a high-multiplicity infection. (A) MDBK cells cultured on a 40 mm glass coverslip were infected with 10
PFU/cell of BHV-1-UL49-EYFP and z-stacks were collected every hour from 2 h to 20 h p.i. The settings for the confocal microscope were kept constant during the experiment. (B) The
kinetics of the nuclear accumulation of unmodiﬁed VP22 in infected cells. MDBK cells cultured on Lab-Tek chamber slides and infected with 10 PFU/cell of wt BHV-1 were ﬁxed at
indicated time points, followed by immunostaining with VP22-speciﬁc serum and FITC-conjugated secondary antibody.
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Fig. 4. Mitosis-dependent nuclear translocation of VP22-EYFP in BHV-1-UL49-EYFP-
infected cells at early stages of infection. MDBK cells grown on a 40 mm glass coverslip
were infected with 5 PFU/cell of the recombinant virus and the coverslip was
assembled into the FCS2 temperature control chamber. (A) VP22-EYFP binds chromatin
in mitotic cells (panel a, arrows) and remains in the nuclei of daughter cells after the
nuclear membrane re-assembly (panel b, arrows). (B) At 4 h p.i. a cell with VP22-EYFP-
decorated chromatin of metaphase chromosomes was selected (0′), and images of this
area were collected every 10 min.
194 V.A. Lobanov et al. / Virology 396 (2010) 189–202infection BHV-1 VP22 retained the ability to translocate from the
cytoplasm to the nucleus of mitotic cells, but only at very early stages
of infection.
Subcellular localization of three differently phosphorylated isoforms of
BHV-1 VP22 during infection
BHV-1 VP22 possesses a functional non-classical NLS as well as a
CRM1-dependent nuclear export signal (Zheng et al., 2005). The
presence of both signals enables proteins to shuttle between the
nucleus and the cytoplasm (Jiang et al., 2006; Kondoh et al., 2006;
Lischka et al., 2006; Marques et al., 2003; Sherman et al., 2001;
Verhagen et al., 2006a,b; Zheng et al., 2004). Although some data
show that a steady state cytoplasmic localization of shuttling proteins
might be caused by a higher rate of their nuclear export (Sherman et
al., 2001; Vecchi et al., 2001), we excluded this possibility based on
the lack of any detectable nuclear accumulation of VP22 during its
early cytoplasmic stage in the presence of a speciﬁc CRM1-dependent
nuclear export inhibitor, leptomycin B (Fukuda et al., 1997) (data not
shown).
To gain further insight into the mechanism regulating the
trafﬁcking of VP22 in infected cells, we considered its phosphorylation
which is the most common regulatory mechanism of nuclear import
and export of key viral gene products (reviewed in Alvisi et al., 2008).
To determine the number and phosphorylation status of BHV-1 VP22
isoforms, whole-cell extracts of MDBK cells infected with 10 PFU/cell
of wt BHV-1 and labeled with either [35S]methionine-cysteine or [32P]orthophosphate were immunoprecipitated with VP22-speciﬁc anti-
bodies, followed by SDS-PAGE and autoradiography. Three closely
migrating VP22 isoforms were precipitated from the 16-h whole-cell
lysate of wt BHV-1-infected 35S-labeled cells (Fig. 5A, lane 3), but not
from the extract of the UL49 deletion mutant-infected cells (lane 1).
The isoforms are marked as a, b, and c, where form c is the slowest-
migrating form, and form a has the highest mobility. All three forms
were detectable in the 8-h sample, but the amount of form c was
comparatively low (lane 2). Dephosphorylation of the immunopre-
cipitated VP22 with lambda protein phosphatase (λ-PPase) resulted
in the displacement of isoforms b and c and appearance of a higher
amount of form a (lane 4), indicating that isoform a is not
phosphorylated, whereas isoforms b and c contain phosphates.
These results were conﬁrmed by an [32P]orthophosphate incorpora-
tion assay. Form c and to a lesser extent form b were labeled with
[32P]orthophosphate, but not isoform a (lane 5).
The subcellular distribution of VP22 isoforms at different stages of
infection was examined by Western blot analysis of the cytoplasmic
and nuclear fractions of MDBK cells infected for 8 h, 12 h, or 16 h with
10 PFU/cell of wt BHV-1 (Fig. 5B). In agreement with our microscopy
data, VP22 partitioned predominantly to the cytoplasmic fraction at
8 h p.i. and the amount of VP22 in the cytoplasm gradually declined by
16 h p.i. (compare lanes 1, 3 and 5) as the protein started to
accumulate in the nucleus between 8 and 12 h p.i. (compare lanes 2
and 4). The presence of low levels of VP22 in the 8-h nuclear fraction
was anticipated as we have shown that at any time during infection
there was a subpopulation of postmitotic cells with nuclear
localization of VP22 (Fig. 4).
The analysis of the distribution of VP22 isoforms showed that the
low-mobility form was seen only in the nuclear fractions at all time
points presented here (Fig. 5B, lanes 2, 4 and 6). Two other forms
partitioned to the cytoplasmic and nuclear fractions at 8 and 12 h p.i.
(lanes 1–4). At this point, the subcellular distribution of BHV-1 VP22
isoforms was very similar to that described for its HSV-1 homologue
(Pomeranz and Blaho, 1999). However, we extended the time of
analysis and showed that, while a low amount of two faster migrating
isoforms was still detectable in the 16-h cytoplasmic fraction (lane 5),
these forms were replaced by two higher mobility bands in the 16-h
nuclear fraction (lane 6). Apparently these bands represent further
posttranslational modiﬁcations of VP22 in the nucleus rather than
degradationof theproteinduring sample processing as similar products
were not detected in the 12-h nuclear fraction (lane 4). In addition,
VP22-speciﬁc antibody-reactive bands with molecular masses close to
45 kDa were detected in the 12-h and 16-h nuclear fractions (lanes 4
and 6). The mobility shift of these bands suggests that they may
represent very stable complexes formed by VP22 and some nuclear
proteins with molecular masses about 10–15 kDa, for instance, core
histones (Ren et al., 2001a). Alternatively, this shift may be caused by
some type of additional posttranslational modiﬁcation in the nucleus,
such as, for example, sumoylation or ubiquitylation (Geiss-Friedlander
and Melchior, 2007). To validate the fractionation procedure the
membrane was stripped and re-probed with antibodies against
cytoplasmic (tubulin) and nuclear (ﬁbrillarin) marker proteins
(Fig. 5B). According to these data it seems likely that VP22 phosphory-
lation isnot absolutely required for themassive nuclear accumulation of
the protein at late stages of infection as the nonphosphorylated isoform
was also detectable in the nucleus after the onset of this process.
The cut-off for the passive diffusion of proteins through the
nuclear pore complex (NPC) is about 50 kDa (reviewed in Macara,
2001). Although the comparatively small molecular mass of the
monomeric form of BHV-1 VP22 would allow nuclear entry by passive
diffusion, the nuclear translocation kinetics of wild-type VP22 was
similar to that of the VP22-EYFP fusion protein (Fig. 3). This suggests
that like HSV-1 VP22, which has the ability to homo-oligomerize or to
be cross-linked by interactions with other viral proteins (Mouzakitis
et al., 2005), BHV-1 VP22 also forms higher-order complexes in
Fig. 5. Analysis of the phosphorylation state and subcellular partitioning of BHV-1 VP22 isoforms. (A) Immunoprecipitation of VP22 from infected cell lysates. MDBK cells were
infected with wt BHV-1 (WT) or UL49-null mutant virus (ΔUL49) at a MOI of 10 and labeled in the presence of either [35S]methionine-cysteine or [32P]orthophosphate. Whole-cell
extracts collected at 8 h (lane 2) or 16 h p.i. (lanes 1, and 3 to 5) were subjected to immunoprecipitation with VP22-speciﬁc antibody. One wt BHV-1-infected 35S-labeled sample was
treatedwithλ-PPase after immunoprecipitation (lane 4). The protein-antibody complexeswere analyzed by SDS-10% PAGE in a 16×16 cm gel and autoradiography. The three closely
migrating electrophoretic forms of VP22 are indicated on the right of the panel as a, b, and c. (B) Subcellular localization of VP22 isoforms. MDBK cells cultured in 100-mm tissue
culture dishes were infected with 10 PFU/cell of wt BHV-1 or mock-infected. The cells were collected by trypsinization at 8, 12 or 16 h p.i., and proteins from the cytoplasmic and
nuclear compartments were selectively isolated as described in Materials and methods. The resulting fractions were analyzed by long SDS-10% PAGE in a 16×16 cm gel, followed by
immunoblotting with anti-VP22 antibody. The stable complexes between VP22 and some nuclear proteins are labeled by the asterisk, and the products with a higher mobility than
that of threemain VP22 isoforms are labeled by arrowheads on the right of the top panel. The fractionation procedure was validated by detection of cytoplasmic (tubulin) and nuclear
(ﬁbrillarin) marker proteins. The values on the left of the panels are molecular masses in kilodaltons. (C) and (D) Immunoblot analysis of VP22 from wt BHV-1-infected cells under
denaturing and non-denaturing conditions, respectively. VP22 monomers and dimers are indicated. The values on the left side of the panels are molecular masses in kilodaltons.
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infected for 8 h with 10 PFU/cell of wt BHV-1 or the UL49-knockout
virus. The extracts were prepared under non-denaturing conditions to
preserve the native conformation of the proteins. The obtained
samples were analyzed by SDS-PAGE with or without boiling in the
presence of 2-mercaptoethanol, followed by immunoblotting with
VP22-speciﬁc serum. No VP22-speciﬁc bands were detected in the
extracts of the UL49 deletionmutant-infected cells (Figs. 5C and D). As
we showed earlier, a 35 kDa band corresponding to the VP22
monomer was seen under denaturing conditions (Fig. 5C). However,
VP22 was represented mainly by a dimer under non-denaturing
conditions (Fig. 5D) suggesting that the formation of higher order
complexes by the protein can contribute to the absence of massive
nuclear accumulation of BHV-1 VP22 at early stages of infection. It is
important to note that the last experiment was performed using mini
SDS gels which provided separation conditions that did not allow
resolving VP22 isoforms.
VP22-EYFP translocates to the nucleus at early stages of infection after
the addition of a strong heterologous NLS, and 131PRPR134 residues are
not required for the massive late nuclear accumulation of the protein
In the next set of experiments we sought to determine if the
prolonged cytoplasmic localization of VP22 could be caused bytemporal strong retention of the protein in the cytoplasm or by
masking of its NLS as a result of multimerization or interactions with
other viral proteins. The second goal was to examine howmutation of
the VP22 NLS inﬂuences the late inﬂux of the protein into the nucleus.
To that end, we constructed two recombinant viruses expressing
either VP22-EYFP with the NLS from the SV40 large-T-antigen
(Kalderon et al., 1984) fused to the C terminus of the protein
(VP22-EYFP-NLS) or with VP22 NLS residues 131PRPR134 substituted
by alanines (VP22-EYFP-mNLS) (Fig. 6A). Western blot analysis
conﬁrmed identical efﬁciency of expression of fusion proteins by
these new recombinants and BHV-1-UL49-EYFP (Fig. 6B). Further-
more, all recombinant viruses grew to wild-type titers in cell culture
(data not shown). The results of live-cell microscopy of MDBK cells
infected at high MOI with BHV-1 recombinants expressing the
different VP22 fusions were as follows.
As soon as ﬂuorescence of the fusion protein bearing the SV40
large-T-antigen NLS became detectable (around 4 h p.i.) the
protein was readily seen in the nuclei of infected cells (Fig. 6C),
whereas in agreement with our previous results VP22-EYFP
remained in the cytoplasm until 8 h p.i. (Fig. 6C). The observation
that a strong heterologous NLS could instantly direct VP22-EYFP-
NLS protein to the nucleus suggests that the VP22 NLS is
nonfunctional or masked by excessive protein–protein interactions
during infection.
Fig. 6. The addition of a strong heterologous NLS to VP22-EYFP leads to predominantly nuclear localization of the resulting fusion protein. (A) Schematic diagram of VP22-EYFP and
fusion proteins with the SV40 large-T-antigen NLS motif PKKKRKV attached to the C terminus (VP22-EYFP-NLS) or the VP22 NLS mutated to alanines (VP22-EYFP-mNLS). (B) The
expression kinetics of VP22-EYFP, VP22-EYFP-NLS or VP22-EYFP-mNLS fusion proteins inMDBK cells infected with corresponding BHV-1 recombinants at aMOI of 10. The whole cell
extracts were prepared from cells harvested at indicated time points and analyzed by immunoblotting with anti-VP22 antibody. M, whole-cell extract of mock-infected cells. The
values on the left of the panel are molecular masses in kilodaltons. (C) Live-cell imaging of subcellular localization of VP22-EYFP-NLS and VP22-EYFP during infection. MDBK cells
cultured in 35-mm glass-bottom culture dishes were infected with corresponding recombinant viruses at a MOI of 10. To stain the nuclei Hoechst was added to the media 40 min
before the acquisition of confocal images at 4, 6 or 8 h p.i.
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EYFP-mNLS fusion protein with the VP22 NLS substituted by
alanines showed that the introduced mutation did not change the
kinetics of its late massive nuclear translocation (Fig. 7). Both VP22-
EYFP-mNLS and VP22-EYFP proteins remained in the cytoplasm up
to 8 h p.i. The nuclear translocation of both proteins started between
8 and 10 h p.i. and by 12 h p.i. the proteins were detected in the
nuclei of the entire monolayer. These results suggest that the late
massive nuclear accumulation of VP22 does not depend on its
131PRPR134 NLS motif.
However, the two proteins demonstrated some important differ-
ences. First, VP22-EYFP-mNLS was diffusely distributed in the
nucleoplasm and did not display any apparent co-localization with
marginalized host chromatin (Fig. 8, compare EYFP andHoechst signal
patterns for both proteins at 10 h p.i.), indicating that the introducedmutation weakened the binding of VP22 to the chromatin. Secondly,
more detailed examination of a number of images of MDBK cells
infected with these BHV-1 recombinants for 6 or 8 h showed that
during the early cytoplasmic stage a small subpopulation of VP22-
EYFP is present in the nucleus in discrete dot-like domains, whereas
the mutation of VP22 NLS completely abrogated this phenomenon
(Fig. 8). The last observation raises the possibility that the 131PRPR134
motif can contribute to the complex pattern of VP22 subcellular
localizations at some stage during infection.
Discussion
To analyze the subcellular localization of BHV-1 VP22 during
productive infection, we constructed a recombinant BHV-1 expressing
VP22 with a C-terminal EYFP fusion. As expected, the introduced
Fig. 7. Subcellular localization of VP22-EYFP-mNLS and VP22-EYFP during infection. The infections were performed as described in the legend for Fig. 8. Live-cell confocal imaging of
EYFP and Hoechst signals was performed at indicated time points.
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and the VP22-EYFP fusion protein was packaged into the extracellular
virus particles. VP22-EYFP also retained trafﬁcking properties iden-
tical to unmodiﬁed VP22. At low MOI both proteins displayed three
unique subcellular distributions within different cells of well-
developed plaques, namely cytoplasmic, equal distribution through-
out the cell, and predominantly nuclear. Nuclear localization of the
proteins was detected within the cells located in the center of a
plaque, which are at a late stage of infection, whereas within the cells
located closer to the periphery of a plaque both proteins were
cytoplasmic. These data demonstrate that like its HSV-1 homologue
(Kotsakis et al., 2001; Pomeranz and Blaho, 1999), de novo expressed
BHV-1 VP22 and its EYFP-tagged variant are not immediately targeted
to the nucleus but remain in the cytoplasm of infected cells and
translocate to the nucleus at a later stage of infection. The data
obtained by time-lapse live imaging of cells infected with BHV-1-
UL49-EYFP at high multiplicity allowed us to distinguish three
different pathways of nuclear translocation of VP22.(i) At very early time points after infection VP22-EYFP employed a
mitosis-dependent nuclear translocation pathway, and accumulated
in the nuclei of postmitotic cells. Like its HSV-1 counterpart (Elliott
and O'Hare, 2000), BHV-1 VP22-EYFP associated with mitotic
chromatin and was retained in the nuclei of daughter cells after
nuclear membrane re-assembly. This phenomenon was detected up
to 5 h p.i. but not at later time points. At later times structures
resembling condensed chromosomes located in a prometaphase-like
pattern were labeled with VP22-EYFP in a small subpopulation of
infected cells (data not shown). This observation suggests inhibition
of mitosis in BHV-1-infected cells and is consistent with earlier
evidence demonstrating a mitotic block imposed by HSV-1 infection
and characterized by the presence of condensed chromosomes
located in a prometaphase-like arrangement (Everett et al., 1999;
Lomonte et al., 2001).
(ii) The late massive nuclear translocation of VP22 was the most
prominent pathway. In cells that did not enter mitosis the protein
remained in the cytoplasm up to 9 h p.i. and gradually accumulated in
Fig. 8. Detection of a small subset of VP22-EYFP in the nucleus in discrete dot-like
domains at early stages of infection and complete abrogation of this phenomenon by
the mutation of the VP22 NLS. Zoomed images of live MDBK cells infected for 6 or 8 h
with 10 PFU/cell of BHV-1 recombinants expressing either UL49-EYFP or UL49-EYFP-
mNLS are presented. The dot-like accumulations of VP22-EYFP are indicated by arrows.
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the mechanism of this translocation pathway remains to be
elucidated, we show here that the VP22 NLS is not required for this
process, as the VP22-EYFP fusion protein with the NLS residues
131PRPR134 substituted with alanines was still able to use this
translocation pathway with wild-type kinetics. As the molecular
mass of unmodiﬁed VP22 is below the limit for passive diffusion of
molecules through nuclear pores (Macara, 2001), one could expect
earlier nuclear accumulation when compared to VP22-EYFP, the mass
of which exceeds this limit. However, we conﬁrmed that both proteins
started the late massive translocation process at the same time. This
implies that the process is tightly regulated. One of the potential
regulatory mechanisms is a reversible retention of VP22 in the
cytoplasm by binding to some cellular structures. Thus, the evidence
that HSV-1 VP22 binds to cellular microtubules (Harms et al., 2000),
and that the microtubule reorganization and the start of nuclear
accumulation of VP22 in HSV-1-infected cells coincide led to the
hypothesis that microtubule fragmentation initiates delayed nuclear
translocation of the protein (Kotsakis et al., 2001). Although with
lower efﬁciency, BHV-1 VP22 is also able to bind and rearrange
cellular microtubules (Harms et al., 2000). In addition, in our
experiments the most abundant high molecular mass protein co-
immunoprecipitated with BHV-1 VP22 was determined by MS/MS
mass spectrometry to be non-muscle myosin heavy polypeptide IIA
(gi|119892775) (V.A. Lobanov, unpublished data). Although it
remains to be clariﬁed if this interaction is direct or indirect, this
ﬁnding suggests that like its HSV-1 homologue (van Leeuwen et al.,
2002) BHV-1 VP22 is involved in a complex formation with an actin-
associated motor protein (Sellers, 2000). However, it seems unlikely
that binding to cytoskeletal ﬁlaments could delay the passive diffusion
of unmodiﬁed VP22 to the nucleus as we showed here that the
addition of the SV40 large-T-antigen NLS to VP22-EYFP instantly
directed the resulting protein to the nucleus, suggesting that the
passive diffusion of unmodiﬁed VP22 is also not completely abolished
by binding to the cytoskeleton. A more plausible explanation for the
absence of earlier nuclear accumulation of unmodiﬁed VP22 is that
the protein is unable to diffuse passively through intact NPCs as it is
represented by dimers and probably higher order self-aggregates in
infected cells. Our immunoblotting data showing that BHV-1 VP22 is
mostly represented by dimers under non-denaturing conditions are inagreement with this assumption and an earlier study demonstrating
that HSV-1 VP22 can homo-oligomerize or be cross-linked by
interactions with other viral proteins (Mouzakitis et al., 2005).
(iii) At early stages of high-multiplicity infection, when VP22-EYFP
was predominantly cytoplasmic, a small subset of the protein was
detected in discrete dot-like domains in the nucleus. The same
phenomenon was earlier ascribed to HSV-1 VP22 (Hutchinson et al.,
2002). Our data demonstrate complete abrogation of this phenom-
enon by the mutation of the VP22 NLS 131PRPR134 motif. This ﬁnding
raises the possibility that the VP22 NLS, although not robust, can drive
the nuclear import of the protein. The fact that the 131PRPR134 motif
was able to direct the EYFP dimer or trimer to the nucleus in
transiently transfected cells reinforces this contention (Zheng et al.,
2005). Alternatively, this motif may be essential for accumulation of
VP22 in the dot-like nuclear domains, and the introduced mutation
makes this minor nuclear subset of the protein less discernible due to
its diffuse distribution in the nucleoplasm. Interestingly the titers of
the mutant BHV-1 expressing VP22-EYFP-NLS were equivalent to, or
even slightly higher than those of wt BHV-1 (data not shown). Since
BHV-1 VP22 is not essential in vitro, this may explain why a change in
subcellular localization of VP22 does not affect the virus replication
cycle.
Thus, our data favor the involvement of active nuclear import in
the process of accumulation of a subset of VP22-EYFP in discrete dot-
like nuclear domains during the early cytoplasmic stage. However, the
mechanism driving the late massive nuclear translocation of the
protein remains unclear. Although the molecular mass of the VP22-
EYFP fusion protein exceeds the passive diffusion limit for NPCs, this
does not necessarily imply that active nuclear import is involved in
this translocation process, as dilation of nuclear pores and disassem-
bly of NPCs in MDBK cells infected at high multiplicity with BHV-1
was previously reported (Wild et al., 2005). Furthermore, the start of
the late nuclear accumulation of unmodiﬁed VP22 and VP22-EYFP
proteins observed in our experiments coincided with the time of NPC
disassembly detected by Wild et al. using high-resolution electron
microscopy. The hypothesis that the late massive nuclear accumula-
tion of VP22 is triggered by gross morphological alterations of nuclear
pores during BHV-1 infection, as reported by Wild et al. (2005), is
attractive; however, the data regarding the status of NPCs in HSV-1-
infected cells are inconsistent. First of all, the nuclear pore dilation
during HSV-1 infection was questioned as morphologically normal
nuclear pores were observed by others in infected cells (Mettenleiter
and Minson, 2006). Moreover, it was shown that in HSV-1-infected
cells the dilation of nuclear pores does not lead to the loss of NPCs,
suggesting that the nucleocytoplasmic transport is not severely
affected (Wild et al., 2009). Finally, one study demonstrated that
70-kDa dextran beads injected into the cytoplasm of HSV-1-infected
cells remained predominantly cytoplasmic throughout the infection
course, demonstrating effective nuclear pore gating for molecules
with molecular masses exceeding 70 kDa (Hofemeister and O'Hare,
2008). However, the molecular mass of BHV-1 VP22-EYFP is lower
than that of dextran beads used to conﬁrm normal permeability of
NPCs in HSV-1-infected Vero cells, and it remains to be determined if
this gating phenomenon can be extended to MDBK cells infected with
BHV-1. Since the late massive nuclear inﬂux started when most of the
viral progeny has already emerged from the cell, the early pathways of
VP22 nuclear accumulation may be more relevant to the infection
process.
Besides potential diffusion through impaired nuclear pores
another possibility requiring attention is precise regulation of a
VP22 motif conferring to the protein the capacity for nuclear
localization, either by active transport or by piggybacking on another
protein bearing a NLS. Most commonly, phosphorylation regulates the
nuclear import and export of key viral gene products (reviewed in
Alvisi et al., 2008). For BHV-1 VP22 expressed in isolation N-terminal
tyrosine 38 was shown to be the major target for the phosphorylation
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tyrosine 38-to-phenylalanine mutant virus expressed a modiﬁed
protein with a different pattern of tyrosine phosphorylation. This
implies that other residues and not only tyrosine residues can be
phosphorylated in the context of infection. The same authors have
shown that in cells infected with a mutant virus expressing VP22 with
all tyrosines substituted for phenylalanines the protein still accumu-
lated in the nucleus at late stages of infection, indicating that tyrosine
phosphorylation is not required for its nuclear translocation. In order
to provide more information on the phosphorylation status of BHV-1
VP22 we determined that like its HSV-1, HSV-2 and PRV homologues
(del Rio et al., 2002; Geiss et al., 2001; Pomeranz and Blaho, 1999),
BHV-1 VP22 is represented by three isoforms closely migrating in
denaturing gels. While the high-mobility isoform was not phosphor-
ylated, the intermediate- and low-mobility isoforms contained
phosphates. As demonstrated for HSV-1 VP22 (Pomeranz and Blaho,
1999), the low-mobility BHV-1 VP22 isoform was detected exclu-
sively in the nuclear fractions, implying that the protein undergoes
further phosphorylation during or after the onset of nuclear
translocation. All VP22 isoforms were detected in the 12-h nuclear
fraction of BHV-1-infected cells, suggesting that these isoforms
possess similar capability to enter the nucleus. Interestingly,
among VP22 isoforms only the low-mobility form remained in
the 16-h nuclear fraction, as other forms were replaced by two
higher mobility bands, suggesting an additional type of processing
of VP22 after the late massive translocation to the nucleus. The
molecular mass of the high-mobility band in the 16-h nuclear
fraction was close to 27 kDa, which is the predicted mass of the
nascent VP22 polypeptide. This band may represent VP22 stripped
of all earlier acquired post-translational modiﬁcations. Taken
together, these results suggest that although VP22 phosphorylation
might facilitate the late massive nuclear translocation of the protein,
exposing the NLS (reviewed in Alvisi et al., 2008), it is not an
absolute requirement for this process as the highest-mobility
nonphosphorylated isoform was abundant in the 12-h nuclear
fraction collected after the onset of the late massive nuclear
translocation. Alternatively, the non-phosphorylated VP22 isoform
detected in the 12-h nuclear fraction may have a nuclear origination
as a result of dephosphorylation.
In summary, the data presented here suggest that dynamic
subcellular localization of VP22 is strictly and differentially regulated
at different stages of BHV-1 infection, the early pathways of VP22
nuclear accumulation potentially being more relevant to the infection
process as the latemassive nuclear inﬂux starts whenmost of the viral
progeny has already emerged from the cell. Although the precise
mechanisms adjusting the access of VP22 to the nucleus remain to be
determined, the identiﬁcation of several BHV-1 VP22 nuclear
translocation pathways, its phosphorylation status in different cellular
compartments and the importance of the 131PRPR134 motif for the
targeting to discrete dot-like nuclear domains at early time points




MDBK cells were cultured in Eagle's Minimal Essential Medium
(MEM) (Gibco, Burlington, ON) supplemented with 5% fetal bovine
serum (FBS) (Gibco). Wild-type BHV-1 strain 108 and recombinant
virus stock preparation and titration were carried out as described
previously (van Drunen Littel-van den Hurk et al., 1994). The UL49-
knockout virus has been described elsewhere (Liang et al., 1995). Cell
culture medium containing neutralizing BHV-1-speciﬁc bovine serum
was used to overlay infected MDBK cells for experiments involving
viral plaque formation.Viral growth curves
MDBK cells grown in 25-cm2 ﬂasks were infected with prepara-
tions of extracellular virus at a MOI of 0.01. After 1 h of incubation, the
monolayers were washed twice with cell culture medium and fresh
mediumwas added. Starting at 4 h after infection, cell culturemedium
and cells were collected separately every 4 h for 32 h and at 48 h p.i.
The cells, collected into freshly added cell culture medium, were
subjected to two freeze–thaw cycles to release the virus. All samples
were clariﬁed by low-speed centrifugation and stored at−80 °C prior
to the determination of the infectious titer by standard plaque assay
on MDBK cells.
Construction of recombinant BHV-1-UL49-EYFP
A 970 bp UL49 gene 3′-ﬂanking fragment encompassing the
adjacent UL49–UL48 intergenic region and a part of the UL48 gene
was ampliﬁed by PCR using primers 5′-CGCGAGCGGGAGGGCTTTTT-3′
and 5′-CCACGACGCCGTGGTTGAACA-3′ with puriﬁed BHV-1 genomic
DNA as a template. The PCR fragment was ligated into the pBluescript
KS+ plasmid (Stratagene, La Jolla, CA) linearized with EcoRV. The
resultant plasmid was designated pBSKS-C1000. The modiﬁed UL49-
EYFP gene was excised from the pVP22-EYFP plasmid, containing the
EYFP ORF fused in frame to the 3′-terminus of the UL49 ORF from
which the stop-codonwas removed (Zheng et al., 2005), blunted with
the Klenow fragment of DNA polymerase I (Amersham Biosciences,
Baie d'Urfe, PQ) and ligated into pBSKS-C1000 linearized with EcoRI
and blunted as above, creating the transfer plasmid pBSKS-VP22-
EYFP-C1000.
To replace the authentic UL49 gene with the modiﬁed UL49-EYFP
sequence, homologous recombination was carried out in MDBK cells
as follows. MDBK cells cultured in a six-well plate were transfected
with 2 μg of the transfer vector pBSKS-VP22-EYFP-C1000 using
Superfect transfection reagent (Qiagen, Hilden, Germany) and then
infected with approximately 10,000 PFU of wt BHV-1. The infected
cells were harvested into the cell culture medium 48 h after virus
inoculation. The cell suspension was subjected to two freeze–thaw
cycles to release the virus from the cells, clariﬁed by low-speed
centrifugation, and the supernatant was stored at −80 °C as the
progeny virus pool. The virus pool was then screened for the
production of ﬂuorescent plaques. After three rounds of EYFP-positive
plaque selection by limiting-dilution infections, a viral clone was
chosen for subsequent analysis and called BHV-1-UL49-EYFP.
The transfer vectors for the construction of BHV-1 recombinants
expressing either VP22-EYFP with the SV40 large-T-antigen NLS
attached to the C terminus of the fusion protein or VP22-EYFP with
the VP22 131PRPR134 motif mutated to alanines were created as
follows. A fragment containing VP22-EYFP ﬂanked by homology
regions was ampliﬁed using primers 5′-AACGTGGCAAAGAAGGG-
CACTTCG-3′ and 5′-TCGCCACGTACATATGCGCAAAGG-3′, and puriﬁed
BHV-1-UL49-EYFP DNA as a template. The ampliﬁed fragment was
ligated into pGEM3Zf+ vector (Promega) linearized with SmaI,
creating plasmid pUL49-YFP. To introduce the SV40 NLS, a PCR
fragment was ampliﬁed from the pUL49-YFP plasmid using primers
5′-TCTCGCCGCCGCGAACGACATCTTG-3′ and 5′-ATTGTACAGTTATA-
CCTTTCTCTTCTTTTTTGGATCGTACAGCTCGTCCATGCCGAGAGTGATCC-
3′, followed by digestion with AgeI and BsrGI and ligation of a
resulting 755 bps fragment into pUL49-YFP cut with the same
enzymes to produce pUL49-YFP-hNLS. A plasmid encoding VP22-
EYFP with the VP22 NLS mutated to alanines was constructed from
pUL49-YFP by a PCR. Two fragments were ampliﬁed using primer
pairs (4A1for) 5′-ACGAGTACAGCGACCTTTGG-3′, (4A1rev) 5′-TAG-
CACCGGGGGGCGCGGCAGCTGCAGCTGGACCGACGGCGACTGC-3′, and
(4A2for) 5′-AGTCGCCGTCGGTCCAGCTGCAGCTGCCGCGCCCCCC-
GGTGCTAATGC-3′, (4A2rev) 5′-TGAACAGCTCCTCGCCCTTG-3′. The
resulting overlapping PCR fragments were joined together by ampliﬁ-
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was cut with AgeI and NheI and inserted into pUL49-YFP digested
with the same enzymes to create pUL49-YFP-mNLS. All PCR
ampliﬁcations were performed using the HotStar HiFidelity Poly-
merase Kit (Qiagen), in the presence of Q-Solution. After the correct
modiﬁcations were conﬁrmed by sequencing, the transfer fragments
were isolated from pUL49-YFP-hNLS and pUL49-YFP-mNLS plasmids
by digestion with KpnI, HindIII and ScaI and used for the homologous
recombination according to the protocol described above. The
recombinant BHV-1 viruses were subjected to three rounds of plaque
puriﬁcation on MDBK cells.
Antibodies
VP22-speciﬁc polyclonal rabbit serum (Liang et al., 1995) and
monoclonal VP8-speciﬁc antibody (van Drunen Littel-van den Hurk
et al., 1995) have been described previously. GFP-speciﬁc polyclonal
antibody was purchased from Molecular Probes (Eugene, OR).
Polyclonal VP16-speciﬁc rabbit serum was a generous gift from Dr.
Vikram Misra, University of Saskatchewan. VP5-speciﬁc serum was
raised in rabbits against a synthetic peptide GVSRSTSDTELQFKQPPGT-
GEL representing amino acids 1300 to 1321 of BHV-1 VP5 according
to the previously described protocol (Khattar et al., 1996).
Monoclonal α-tubulin-speciﬁc mouse IgG clone DM1A was pur-
chased from Sigma (Saint Louis, MO). Rabbit polyclonal ﬁbrillarin-
speciﬁc antibody H-140 was purchased from Santa Cruz Biotech-
nology (Santa Cruz, CA).
Gradient puriﬁcation of BHV-1 virions
For gradient puriﬁcation of BHV-1 virions, supernatants from
infected MDBK cells displaying complete cytopathic effects were
combined and cell debris was removed by low-speed centrifuga-
tion. Virions were pelleted through a 30% (w/v) sucrose cushion in
PBS by centrifugation in a Beckman SW32Ti rotor for 2 h at
25,000 rpm. The pellet was resuspended in TNE buffer (10 mM
Tris–HCl pH 7.5, 150 mM NaCl, 1 mM EDTA) and layered onto a
36 ml linear 10–60% (w/v) gradient of potassium sodium tartrate
in TNE buffer poured from the bottom using a Hoefer SG50
gradient maker (Amersham, Piscataway, NJ). After centrifugation
for 2 h at 25,000 rpm (SW32Ti), puriﬁed virions were withdrawn
by side puncture with a syringe. The virions were concentrated by
centrifugation for 2 h at 25,000 rpm (SW32Ti), resuspended in TNE
buffer and stored at −80 °C until use.
Viral DNA isolation and analysis
Viral DNAwas isolated from extracellular virions as follows. MDBK
cells were infected with wt or recombinant BHV-1 at a MOI of 0.1, and
the infection was allowed to proceed to completion. The cell culture
supernatant was clariﬁed by centrifugation at 5,000×g for 10 min,
and viral particles were collected by centrifugation at 27,000 rpm
(SW32Ti) for 2 h at 4 °C. DNA was isolated from the pelleted virions
using the Qiagen genomic DNA extraction kit. Viral pellets were
resuspended in 5 ml of buffer G2, followed by the addition of 95 μl of
Qiagen Proteinase K stock solution and incubation at 50 °C for 1 h.
After the incubation, the lysates were diluted with an equal volume of
buffer QBT and loaded into Qiagen Genomic-tip 100/G columns.
Subsequent puriﬁcation stepswere performed strictly according to the
protocol of the manufacturer. An aliquot of each DNA preparation was
digested overnight with SphI in the presence of RNaseA. The DNA
fragments were separated by electrophoresis in a 0.8% agarose gel and
transferred to Zeta-Probe nylonmembrane (Bio-Rad, Hercules, CA) by
standard procedures. Probes used in Southern hybridization were
generated by PCR ampliﬁcation using EYFP gene-speciﬁc primers 5′-
ACGTAAACGGCCACAAGTTC-3′ and 5′-TCACCTTGATGCCGTTCTTC-3′and pEYFP-N1 (Clontech, Mountain View, CA) vector as a template
as well as UL49 gene-speciﬁc primers 5′-TACGAGTACAGCGACCTTTG-
3′ and 5′-CCAGACGCAACAGCATTAGC-3′ and puriﬁed BHV-1 DNA as a
template, followed by [α-32P]dCTP labeling by random priming using
Ready-To-Go DNA labeling beads (-dCTP) (Amersham Biosciences,
Buckinghamshire, UK). The hybridizations were performed according
to standard methods.
Cell fractionation
Cell fractionation was performed using Nuclei EZ Prep lysis
buffer (Sigma) following the manufacturer's guidelines. Brieﬂy, at a
desired time after infection cells were collected by trypsinization.
The cells were washed in PBS by low-speed centrifugation and lysed
on ice for 5 min with the Nuclei EZ lysis buffer. The nuclei were
pelleted by centrifugation at 500×g for 5 min at 4 °C. The
incubation in the lysis buffer and centrifugation was repeated
twice more to remove cytoskeletal components loosely bound to
the nuclei. The supernatants after each wash were pooled together,
concentrated by centrifugation in Amicon Ultra −15 Ultracel—10 K
centrifugal ﬁlter units (Millipore) and stored as cytoplasmic
fractions. After the ﬁnal wash, the nuclei were resuspended in
3 ml of solution S1 (0.25 M sucrose, 10 mM MgCl2, 1 mM PMSF)
and layered over a 3 ml cushion of solution S3 (0.88 M sucrose,
0.5 mM MgCl2, 1 mM PMSF), followed by centrifugation at 2,800×g
for 10 min at 4 °C. Each nuclear pellet was resuspended in 200 μl of
the Nuclei EZ storage buffer. Finally, the concentrations of nuclear
suspensions were determined by counting nuclei using a haemo-
cytometer and equal amounts of nuclei were lysed by incubation for
5 min at 100 °C in 1× SDS loading buffer. The purity of nuclei was
assessed by immunoblotting with α-tubulin-speciﬁc antibody (see
below).
SDS-PAGE and Western blotting
Whole-cell extracts were prepared by resuspension of cell pellets
in RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl, 1% NP-40, 1%
deoxycholate, 0.1% SDS) supplemented with 1 mM PMSF, 1 μg/ml
aprotinin, 1 μg/ml leupeptin and 1 μg/ml pepstatin A, followed by
incubation for 30 min on ice and two short cycles of sonication. The
solubilized virion proteins were prepared by incubation of gradient-
puriﬁed virions in 1× SDS gel-loading buffer at 100 °C for 5 min.
The preparation of total cell extracts under non-denaturing
conditions was performed according to guidelines presented in
the Invitrogen NativePAGE Novex Bis-Tris Gel System brochure.
Brieﬂy, after washing with PBS, infected cell pellets (about 8×106
cells) were resuspended in 400 μl of 1× NativePAGE sample buffer
(50 mM Tris–HCl pH 7.2, 6 N HCl, 50 mM NaCl, 10% (w/v) glycerol,
0.001% Ponceau S) supplemented with 2.5% digitonin and protease
inhibitors. The samples were incubated for 30 min on ice, followed
by centrifugation at 20,000×g for 30 min at 4 °C. Then, MgCl2 was
added to a ﬁnal concentration of 2 mM and 0.5 U of Benzonase/μl of
sample. The samples were incubated for 30 min at room
temperature and centrifuged as above. The supernatants were
used for analysis. The concentrations of the solubilized proteins
were determined using Bio-Rad protein assay dye reagent as
speciﬁed by the manufacturer. Equal amounts of protein prepara-
tions were separated by SDS-PAGE, followed by transfer to
nitrocellulose membranes. Then, the membranes were subjected
to immunoblotting with the appropriate primary antibodies.
Western blots were further processed using alkaline phosphatase-
conjugated goat anti-rabbit IgG (H+L) or anti-mouse IgG (H+L) as
secondary antibodies (Kirkegaard and Perry Laboratories, Gaithers-
burg, MD) and developed with 5-bromo-4-chloro-3-indolyl phos-
phate/nitro blue tetrazolium (Sigma) or Lumi-Phos WB
chemiluminescent substrate (Pierce, Southﬁeld, MI).
201V.A. Lobanov et al. / Virology 396 (2010) 189–202Immunoprecipitation assay
MDBK cells grown in 100-mmcell culture disheswere infectedwith
10 PFU/cell of wt BHV-1 or UL49-null virus. Two hours before the
addition of radioactive label, the monolayers were washed once with
PBSandstarved inDMEM-2%dialyzedFBS lackingmethionine-cysteine
or sodium phosphate. At 6 h p.i., 100 μCi/ml of [35S]methionine-
cysteine or [32P]orthophosphatewas added to the cells. At 8 or 16 h p.i.,
cells were washed with PBS and whole-cell extracts were prepared by
resuspension of the pellets in RIPA buffer supplemented with protease
inhibitor cocktail set III (Calbiochem, San Diego, CA) and incubation on
ice for 30 min. The lysates were clariﬁed at 16,000×g for 5 min at 4 °C
and the 32P-labeled sample was additionally supplemented with
phosphatase inhibitor cocktail set III (Calbiochem). The lysates were
incubated overnight at 4 °C with VP22-speciﬁc serum, followed by
incubation for 4 h at 4 °C with protein A-Sepharose CL-4B (GE
Healthcare, Uppsala, Sweden). After incubation with the beads, one wt
BHV-1-infected 35S-labeled sample was treated with λ-PPase (New
England Biolabs, Pickering, ON), which possesses activity towards
phosphorylated serine, threonine, and tyrosine residues. This sample
was washed twice in 1× λ-PPase buffer, and after the second wash,
beadswere resuspended in 100 μl of λ-PPase buffer containing 2,000 U
of the enzyme, followed by incubation at 30 °C for 1 h. Then, all samples
were washed four times in RIPA buffer, resuspended in sample loading
buffer, and analyzed by SDS-10% PAGE and autoradiography.
Indirect immunoﬂuorescence
MDBK cells cultured on Permanox chamber slides (Lab-Tek,
Naperville, IL) were infected with wt BHV-1 or BHV-1-UL49-EYFP at
a desiredMOI, ormock infected. At different time points after infection,
the cells were rinsed in PBS and ﬁxed in 4% phosphate-buffered
paraformaldehyde for 30 min at room temperature, followed by two
washes in PBS, and permeabilization with chilled 100% acetone at
−20 °C for 3 min. The cells were then washed three times in PBS and
blocked in PBS containing 5% normal goat serum (Gibco). After a rinse
with PBS, the cells were incubated with a primary antibody in PBS
containing 1% goat serum and 0.1% Triton X-100 for 2 h at room
temperature or overnight at 4 °C. After three washes in PBS, the cells
were incubated with appropriate ﬂuorophore-conjugated secondary
antibody for 1 h at room temperature. FITC-conjugated goat anti-rabbit
IgG (H+L) (Zymed Laboratories Inc., S. San Francisco, CA) and highly
cross-adsorbed Alexa Fluor 633-conjugated goat anti-rabbit IgG and
anti-mouse IgG (Invitrogen,Molecular Probes)were used as secondary
antibodies. Subsequently, the cells were extensively washed with PBS
as above. Finally, the slides were covered with coverslips using
Vectashield Hard-Set mounting medium (Vector Laboratories, Burlin-
game, CA). The cells were examined using a Zeiss LSM410 confocal
microscope equipped with external argon ion 488-nm laser.
Live-cell microscopy and time lapse analysis
MDBK cells cultured in 35-mmglass-bottom culture dishes (MatTek
Corporation, Ashland, MA) were used for short-term live-cell analysis.
For long-termtime lapse experiments the cellswere culturedon40-mm
round glass coverslips (Bioptechs, Butler, PA). Prior to the examination,
a coverslip with infected cells was assembled into the Focht live-cell
chamber system (FCS2) (Bioptechs) and the chamber was attached to
a Zeiss LSM410 confocal system equipped with an objective heater
(Bioptechs). In order to reduce the ﬂuorescence background, phenol
red-free Dulbecco's modiﬁed Eagle medium (DMEM) (Gibco)
supplemented with 2% FBS was used for the cell monolayer perfusion
during time-lapse experiments. A z-series of images was acquired
with a desired time interval and then processed to produce an
individual z-image for each time point using Image J version 1.37c
software (Wayne Rasband, National Institutes of Health, USA).Acknowledgments
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